Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The failure of many molecules as CNS bioactive compounds is due to many restrictions: poor water solubility, intestinal absorption, in vivo stability, bioavailability, therapeutic effectiveness, side effects, plasma fluctuations, and difficulty crossing physiological barriers, like the brain blood barrier (BBB), to deliver the drug directly to the site of action. AREA COVERED: Nanotechnology-based approaches with the employment of liposomes, micelles, dendrimers, and solid lipid nanoparticles (SLN) as drug delivery systems, are used to overcome the above reported limitations. Here, we focus on the delivery of drugs based on SLN formulation to treat neurodegenerative diseases. Notably, SLN have the ability to protect drugs from chemical and enzymatic degradation, direct the active compound towards the target site with a substantial reduction of toxicity for the adjacent tissues, and pass physiological barriers increasing bioavailability without resorting to high dosage forms. EXPERT OPINION: We believe that SLN could represent a suitable tool to pass the BBB and permit drugs to reach damaged areas of the CNS in patients affected by neurodegenerative pathologies, such as Alzheimer's and Parkinson's diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“receptors on brain capillary endothelial cells allowing them to pass.[19] Another strategy to improve the drug concentration in the CNS is represented by the use of ligands merged to the surface of SLN: antibodies, proteins, peptides, or small molecules that, joined to the nanoparticles surface, can be used as Trojan…”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · cited 1×
“[51] To date, three acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are approved by the FDA to manage AD from mild to moderate.[52] The treatment with donepezil, rivastigmine, or galantamine contributes to maintain thinking, memory, and speaking skills and may help with the stabilization of…”
BackgroundSandhir, R., Yadav, A., Mehrotra, A., Sunkaria, A., Singh, A., & Sharma, S. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8261-y · Cited by 204
Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
Esposito, E., Fantin, M., Marti, M., Drechsler, M., Paccamiccio, L., Mariani, P., Sivieri, E., Lain, F., Menegatti, E., Morari, M., et al. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9514-y · Cited by 183 · cited 2×
“In vivo studies indicated a more rapid antiparkinsonian action of encapsulated BK compared to free BK [39]”
BackgroundMethodBondì, M. L., Craparo, E. F., Giammona, G., & Drago, F. (2010) · Nanomedicine · doi:10.2217/nnm.09.67 · Cited by 175
Pardeshi, C. V., Rajput, P. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Drug Delivery · doi:10.3109/10717544.2012.752421 · Cited by 141
Tsai, M.-J., Huang, Y.-B., Wu, P.-C., Fu, Y.-S., Kao, Y.-R., Fang, J.-Y., & Tsai, Y.-H. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22285 · Cited by 137 · cited 2×
“[40] Prompt by the discouraging data of oral bioavailability of apomorphine (Figure 3), a dopamine receptor agonist, which is <2% because of the intense first-pass effect and degradation phenomena in the gastrointestinal tract,[41] Tsai et al.”
Background
Cited by
Nano-based smart pesticide formulations: Emerging opportunities for agriculture
Kumar, S., Nehra, M., Dilbaghi, N., Marrazza, G., Hassan, A. A., & Kim, K.-H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.012 · Cited by 778
Recent advances in polymeric drug delivery systems
Sung, Y. K., & Kim, S. W. (2020) · Biomaterials Research · doi:10.1186/s40824-020-00190-7 · Cited by 732
Nanostructured lipid carriers for site-specific drug delivery
Khosa, A., Reddi, S., & Saha, R. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.055 · Cited by 619
Nanoparticles in Drug Delivery: From History to Therapeutic Applications
Afzal, O., Altamimi, A. S. A., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., et al. (2022) · Nanomaterials · doi:10.3390/nano12244494 · Cited by 468
Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., & Emiliani, C. (2019) · Journal of Functional Biomaterials · doi:10.3390/jfb10010004 · Cited by 468
Metadata
- Authors
- Cacciatore, I., Ciulla, M., Fornasari, E., Marinelli, L., & Di Stefano, A.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2016-05-03
- Volume
- 13
- Issue
- 8
- Pages
- 1121-1131
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2336643532
- Cited by
- 153
- References
- 12
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. https://app.cochat.ai/papers/10.1080/17425247.2016.1178237
- The paper
- Cacciatore, I., Ciulla, M., Fornasari, E., Marinelli, L., & Di Stefano, A. (2016). Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2016.1178237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.